A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis

Arthritis and Rheumatism

Volumn 62, Issue 2, 2010, Pages 580-588

  Farina, G ^a   Lafyatis, D ^a   Lemaire, R ^a   Lafyatis G Farina, R ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARTILAGE OLIGOMERIC MATRIX PROTEIN; INTERFERON; INTERFERON INDUCIBLE PROTEIN 44; RNA; SIALOADHESIN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MULTIPLE REGRESSION; OUTCOME ASSESSMENT; PATIENT CARE; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; REGULATORY MECHANISM; SAMPLE; SCORING SYSTEM; SKIN; SKIN BIOPSY; SKIN DISEASE; SYSTEMIC SCLEROSIS; VALIDATION STUDY;

ANTIGENS; BIOPSY; CYTOSKELETAL PROTEINS; EXTRACELLULAR MATRIX PROTEINS; GENETIC MARKERS; GENETIC TESTING; GLYCOPROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; PREDICTIVE VALUE OF TESTS; RECEPTORS, IMMUNOLOGIC; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA;

EID: 75749095228     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27220     Document Type: Article

References (34)

1. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
2. Yee CS, Farewell V, Isenberg DA, Prabu A, Sokoll K, Teh LS, et al. Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 2006;54:3300-5.
3. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
4. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
5. Furst D, Khanna D, Matucci-Cerinic M, Clements P, Steen V, Pope J, et al. Systemic sclerosis: continuing progress in developing clinical measures of response [review]. J Rheumatol 2007;34:1194-200.
6. Furst DE. Outcome measures in rheumatologic clinical trials and systemic sclerosis. Rheumatology (Oxford) 2008;47 Suppl 5:v29-30.
7. Czirjak L, Nagy Z, Aringer M, Riemekasten G, Matucci-Cerinic M, Furst DE. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 2007;66:966-9.
8. Pope JE, Baron M, Bellamy N, Campbell J, Carette S, Chalmers I, et al. Variability of skin scores and clinical measurements in scleroderma. J Rheumatol 1995;22:1271-6.
9. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004;138:540-6.
10. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6.
11. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, et al. Circulating endothelin-1 levels in systemic sclerosis subsets: a marker of fibrosis or vascular dysfunction? J Rheumatol 1994;21:1838-44.
12. Lee YJ, Shin KC, Kang SW, Lee EB, Kim HA, Song YW. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis. Clin Exp Rheumatol 2001;19:69-74.
13. Scheja A, Wildt M, Wollheim FA, Akesson A, Saxne T. Circulating collagen metabolites in systemic sclerosis: differences between limited and diffuse form and relationship with pulmonary involvement. Rheumatology (Oxford) 2000;39:1110-3.
14. Stone PJ, Korn JH, North H, Lally EV, Miller LC, Tucker LB, et al. Cross-linked elastin and collagen degradation products in the urine of patients with scleroderma. Arthritis Rheum 1995;38:517-24.
15. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, et al. Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-33.
16. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993;122:103-11.
17. Kissin EY, Merkel PA, Lafyatis R. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum 2006;54:3655-60.
18. Farina G, Lemaire R, Pancari P, Bayle J, Widom RL, Lafyatis RA. Cartilage-oligomeric-matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor-β. Ann Rheum Dis 2009;68:435-41.
19. York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and Toll-like receptor agonists. Arthritis Rheum 2007;56:1010-20.
20. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
21. -ΔΔCt method. Methods 2001;25:402-8.
22. Farina G, Wisdom RL, Strehlow D, Gardner H, Korn JH. Gene expression profiling in scleroderma: confirmation of results using real-time quantitative PCR [abstract]. Arthritis Rheum 2002;46 Suppl:S351.
23. Gardner H, Strehlow D, Bradley L, Widom R, Farina A, de Fougerolles A, et al. Global expression analysis of the fibroblast transcriptional response to TGFβ. Clin Exp Rheumatol 2004;22 Suppl 33:S47-57.
24. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 2008;3:e2696.
25. Xu SW, Howat SL, Renzoni EA, Holmes A, Pearson JD, Dashwood MR, et al. Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. J Biol Chem 2004;279:23098-103.
26. Gore-Hyer E, Shegogue D, Markiewicz M, Lo S, Hazen-Martin D, Greene EL, et al. TGF-βand CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol 2002;283:F707-16.
27. Kaviratne M, Hesse M, Leusink M, Cheever AW, Davies SJ, McKerrow JH, et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-β independent. J Immunol 2004;173:4020-9.
28. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, et al. Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50:3958-67.
29. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998;95:15623-8.
30. Varga J, Olsen A, Herhal J, Constantine G, Rosenbloom J, Jimenez SA. Interferon-γ reverses the stimulation of collagen but not fibronectin gene expression by transforming growth factor-β in normal human fibroblasts. Eur J Clin Invest 1990;20:487-93.
31. Duncan MR, Berman B. Gamma interferon is the lymphokine and β interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation. J Exp Med 1985;162:516-27.
32. Qing J, Liu C, Choy L, Wu RY, Pagano JS, Derynck R. Transforming growth factor β/Smad3 signaling regulates IRF-7 function and transcriptional activation of the β interferon promoter. Mol Cell Biol 2004;24:1411-25.
33. Kissin EY, Schiller AM, Gelbard RB, Anderson JJ, Falanga V, Simms RW, et al. Durometry for the assessment of skin disease in systemic sclerosis. Arthritis Rheum 2006;55:603-9.
34. Merkel PA, Silliman NP, Denton CP, Furst DE, Khanna D, Emery P, et al. Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis Rheum 2008;59:699-705.